EVT 401 - P2X7-Antagonist

EVT 401 - P2X₇ antagonist - Inflammatory Diseases

Evotec has announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT 401, a selective, small molecule P2X7 antagonist, in the companion animal market. Evotec is entitled to receive technology access fees, development and commercial milestone payments, and significant tiered royalties on net sales. Evotec retains all rights to the programme for human therapeutic use.

The P2X7 receptor is an ATP-gated ion channel primarily expressed on cells of the immune system and is thought to play an important role in inflammatory processes through the regulation of a number of proinflammatory cytokines such as IL-1ß. P2X7 receptor antagonism may therefore provide a novel approach for the treatment of inflammatory conditions.

Evotec partners P2X7 antagonist programme, EVT 401, to a top tier global animal health company